The SardiNIA study is a longitudinal population-based health study including 6,602 individuals from the Lanusei valley on Sardinia. The participants have been genotyped on four different Illumina Infinium arrays, OmniExpress, Cardio-Metabochip85 (link), Immunochip86 (link), and Exome Chip). Samples with low call rate or with discrepancies between inferred and reported sex and/or relationships were excluded. After genotyping, variants with low call rates, large discordance among duplicate or identical twin genotypes, excess Mendelian inconsistencies, deviations from Hardy–Weinberg equilibrium, or MAF = 0 were excluded. Variants were then imputed from a SardiNIA-specific sequencing panel (~4× coverage) of 3839 individuals, using Minimac387 (link). Markers with imputation quality R2 > 0.3 (or >0.6 in variants with MAF < 1%) were retained, resulting in a total of ~19 million genetic variants.
Free full text: Click here